CLYM Earnings — Climb Bio, Inc. Common Stock Post-ER Performance | BigEarnings
CLYM — Climb Bio, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$12.70
Market Cap$727.2M
P/E—
52W Range$1.35 – $14.41
Next Earnings2026-08-11
About Climb Bio, Inc. Common Stock
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
